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Abstract
Background: Hexokinase-2(HK-2) plays dual roles in glucose metabolism and mediation of cell apoptosis, making it
an attractive target for cancer therapy. Chrysin is a natural flavone found in plant extracts which are widely used as
herb medicine in China. In the present study, we investigated the antitumor activity of chrysin against
hepatocellular carcinoma (HCC) and the role of HK-2 played for chrysin to exert its function.
Methods: The expression of HK-2 in HCC cell line and tumor tissue was examined by western blotting and
immunohistochemistry staining. The activities of chrysin against HCC cell proliferation and tumor glycolysis were
investigated. Chrysin-induced apoptosis was analyzed by flow cytometry. The effect of chrysin on HK-2 expression
and the underlying mechanisms by which induced HCC cell apoptosis were studied. In HK-2 exogenous
overexpression cell, the changes of chrysin-induced cell apoptosis and glycolysis suppression were investigated.
HCC cell xenograft model was used to confirm the antitumor activity of chrysin in vivo and the effect on HK-2 was
tested in chrysin-treated tumor tissue.
Results: In contrast with normal cell lines and tissue, HK-2 expression was substantially elevated in the majority of
tested HCC cell lines and tumor tissue. Owing to the decrease of HK-2 expression, glucose uptake and lactate
production in HCC cells were substantially inhibited after exposure to chrysin. After chrysin treatment, HK-2
which combined with VDAC-1 on mitochondria was significantly declined, resulting in the transfer of Bax from
cytoplasm to mitochondria and induction of cell apoptosis. Chrysin-mediated cell apoptosis and glycolysis
suppression were dramatically impaired in HK-2 exogenous overexpression cells. Tumor growth in HCC xenograft
models was significantly restrained after chrysin treatment and significant decrease of HK-2 expression was
observed in chrysin-treated tumor tissue.
Conclusion: Through suppressing glycolysis and inducing apoptosis in HCC, chrysin, or its derivative has a
promising potential to be a novel therapeutic for HCC management, especially for those patients with high HK-2
expression.
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Background
Numerous mutations in oncogenes and tumor suppres-
sors, as well as the alterations in gene expression pro-
files, result in the deregulations of cell metabolism in
cancer cells. The Warburg effect, also named aerobic
glycolysis, which is observed by Otto Heinrich Warburg
in 1920s, is one of most prominent hallmarks of cancer
cells [1]. In Warburg effect, even in the presence of suffi-
cient oxygen, glucose is converted to lactate, instead of
totally oxidized via Krebs cycle to generate ATP [2].
Tumor glycolysis supplies abundant energy to sustain
the rapid tumor growth, moreover, the product of gly-
colysis such as lactate also provides an appropriate
microenvironment to promote tumor metastasis [3]. So
far, various regulatory pathways involved in the conver-
sion from the Krebs cycle to tumor glycolysis have been
well investigated, HKs were considered to be one of the
most important effectors [4, 5].
As important glycolytic enzymes, HKs are responsible
for the first rate-limiting step in the process of glucose
metabolism, in which glucose is phosphrylated to
glucose-6-phosphate. Four different isoforms of HKs,
named as HK1-4 have been identified so far. HK-1 and
HK-2 are mainly located on the outer membrane of
mitochondria, HK-3 is positioned in a perinuclear com-
partment, and HK-4 is in the cytoplasm. Localization to
the outer membrane of mitochondria confers HK-2 the
advantage to escape product inhibition and gain prefer-
ential access to ATP in mitochondrion [6]. Among these
different HKs, HK-2 is found to be expressed of high
rate in malignant tumors and plays a key role in the de-
velopment of Warburg phenotype. Overexpression of
HK-2 was observed in various cancers, such as gastric
[7], ovarian [8], breast cancer [9], cervical carcinoma
[10], esophageal adenocarcinoma [11] and nasopharyn-
geal carcinoma [12].
Chrysin is a bioactive flavone derived from plant ex-
tracts such as blue passion flower, propolis, and honey,
which are widely used as herb medicine in China. Except
its multiple bioactivities in antioxidant [13], anti-
inflammatory [14] and antibacterial [15], its antitumor
potential is also well validated in a variety of human can-
cer cell lines. Chrysin is demonstrated to exert antitu-
mor effect by inducing cell cycle arrest and apoptosis
through different mechanisms, for instance, activation of
extrinsic apoptosis pathway [16], alteration of cyclins
and CDKs [17]. Moreover, multiple signaling pathways
in cancer cells, such as Ras-Raf-MAPKs, PI3K-Akt,
STAT, NF-κB, Wnt-β-catenin and Notch signaling path-
ways, were proved to be modulated by chrysin to inhibit
cell proliferation, angiogenesis, invasion and metastasis
[18–20]. However, the effect of chrysin on tumor gly-
colysis is largely unknown. Herein, we showed that chry-
sin inhibited glycolysis and induced apoptosis in HCC
cells in vitro and in vivo. Mechanism investigations re-
vealed that the biological activities exerted by chrysin
were mainly attributed to its effect on HK-2. With the
decrease of HK-2, chrysin inhibited tumor glycolysis and
activated mitochondria-associated apoptosis. Given HK-
2 was found to be overexpressed in the majority of HCC
tissue, the results of present study suggested chrysin, or
its analogues, may serve as effective candidates for HCC
management.
Methods
Cell line and reagents
Chrysin and other chemical reagents such as Tris, NaCl,
SDS and DMSO were purchased from Sigma-Aldrich (St.
Louis, MO). The normal human hepatic cell LO2 and
HepG2, Hep3B, Huh-7, HCC-LM3, Bel-7402 and SMMC-
7721 were obtained from the Cell Bank of Chinese
Academy of Sciences and cultured with Dulbecco’s
Modified Eagle Medium containing 10% FBS and 1%
antibiotics in a 37 °C incubator with 5% CO2. Anti-
HK2, anti-VDAC1, anti-cleaved-caspase3, anti-cleaved-
PARP, anti-cytochrome C, anti-Bax, anti-Bak, anti-Bcl-2,
anti-Bcl-xL, anti-rabbit IgG-HRP and anti-mouse IgG-
HRP antibodies were products of Cell Signaling Technol-
ogy, Inc. (Danvers, MA). Anti-α-Tubulin antibody was
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Anti-β-actin (A5316) was product of Sigma
(St. Louis, MO, USA). HK2 (ORF004940) construct was
purchased from Applied Biological Materials (ABM) Inc.
(Richmond, BC, Canada). Lipofectamin 2000 was pur-
chased from Invitrogen (Carlsbad, CA).
Cell proliferation assay
Human HCC cells (3× 103 per well) were seed in 96-well
plate and then treated with or without different concen-
trations of chrysin for 0, 24, 48 and 72 h. Cell viability
was measured with Cell Titer-Glo Luminescent Cell Via-
bility Assay kit from Promega Corp. (Madison, WI) ac-
cording to the manufacturer’s protocol.
Western blotting
Cells were harvested by trypsinization and pelleted by
centrifugation. The pellets were lysed with RIPA buffer
supplemented with protease cocktail (Roche, Germany).
Protein concentrations in cell lysates were determined
with the Bradford assay (Bio-Rad, Philadelphia, PA,
USA). The lysates were subjected to SDS-PAGE and
then electrically transferred to PVDF membrane
(Millipore, Billerica, MA, USA). After blocked with 5%
non-fat dry milk, the membranes were incubated with
specific primary antibodies overnight at 4 °C. After
washed with TBS-Tween 20 three times, HRP-
conjugated secondary antibodies were incubated at room
temperature for 1 h. The membranes were washed with
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TBS-Tween 20 and the bands were visualized using ECL
chemiluminescence reagents (Pierce Chemical Co.,
Rockford, lllinois, USA).
Apoptosis assays
Cells were seeded in six-well plate and then treated with
chrysin for 24 h. After treatment, attached and floating
cells were harvested by centrifugation. For apoptosis
analysis, the cells were re-suspended with PBS and ad-
justed to 1 × 106 cells/ml, then 5 μl Annexin V and Pro-
pidium Iodide staining solution were added to 300 μl of
the cell suspension. After incubated 10–15 min at room
temperature in the dark, stained cells were assayed and
quantified using a FACSort Flow Cytometer (BD, San
Jose, CA, USA).
Glucose uptake and lactate production measurement
Glucose uptake and lactate production measurement
were performed as previously described [21]. Briefly,
Cells were trypsinized and seeded in 6-well plates
(5 × 105), after incubation for 10 h, cell culture
medium was discarded and replaced with fresh cul-
ture medium containing different concentrations of
chrysin for 8 h. Glucose and lactate levels were mea-
sured by using the Automatic Biochemical Analyzer
(7170A, HITACHI, Tokyo, Japan). The relative glu-
cose consumption rate and lactate production rate
were normalized by the protein concentration of
samples.
Isolation of mitochondrial fractions
The cells (5 × 106) from a 10 cm dish were harvested by
trypsinization and centrifuged at 800 rpm for 5 min at
4 °C. The cell pellets were washed once with cold PBS
and then resuspended with isolation buffer (20 mM
Hepes, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM so-
dium EDTA, 1 mM dithiothreitol, 10 mM phenylmethyl-
sulfonyl fluoride, 10 mM leupeptin and 10 mM
aprotinin). After chilling on ice for 3 min, the cells were
disrupted by 60 strokes of a glass homogenizer. The
homogenate was centrifuged at 2,000 rpm for 10 min at
4 °C to remove unbroken cells and nuclei. The
mitochondria-enriched fraction (supernatant) was then
pelleted by centrifugation at 13,000 rpm for 30 min. The
pellets was lysed in RIPA buffer (10 mM Tris-Cl
(pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-
100, 0.1% sodium deoxycholate, 0.1% SDS. 140 mM
NaCl) and analyzed by western blot. For Immunoprecip-
itation, 500 μg extractions were pre-cleared with 30 μl
(50% slurry) agarose A/G beads for 2 h rocking at 4 °C.
The beads were removed, 30 μl (50% slurry) fresh agar-
ose A/G beads and appropriate antibodies (4 μg) were
added to the precleared lysate overnight at 4 °C. The
beads were washed, mixed with 4 × SDS sample buffer,
boiled, and then subjected to Western blotting.
In vivo tumor growth assay
Six-week-old female Nu/nu athymic nude mice were
maintained under specific pathogen free (SPF) condition
in accordance with Institutional Animal Care and Use
Committee. HCC-LM3 cells (5 × 106 cell/mice) were
subcutaneously injected into the right flank of nude
mice. When the tumor volume reached about 100 mm3,
the mice were randomly grouped, five mice per group.
The vehicle group was given 0.5% sodium carboxymeth-
ylcellulose, and the other group received 30 mg/kg chry-
sin. Chrysin was administrated three times weekly via
intraperitoneal injection. The tumors were measured
twice per week using microcalipers and tumor volu-
me(V) was calculated as following: V = (length × width2)/
2. After the experiment, mice were sacrificed and the tu-
mors are weighed and photographed.
Immunohistochemical(IHC) staining
A human HCC tissue array (HlivH150CS03), which con-
tains 75 cases of malignant HCC biopsy and 75 cases of
matched adjacent normal tissue, was purchased from
Shanghai Outdo Biotech Co., Itd. (Shanghai, China).
Tumor tissues from xenograft model were fixed in 4%
paraformaldehyde and then embedded in paraffin. IHC
staining was performed as previously described [22].
Briefly, Paraffin sections were deparaffinized and hy-
drated, the endogenous peroxidase activity was blocked
with 3% H2O2. Antigen retrieval was performed in citric
acid solution using a microwave oven. The tissues were
blocked with serum from the host of the secondary anti-
body and incubated with primary antibody of anti-HK2
(1:200) or anti-Ki67 (1:250) respectively at 4 °C over-
night. Biotinylated secondary antibodies were added at a
1:100 dilution and followed by Vectastin ABC solution.
Finally, the binding of the antibodies was visualized with
3, 3-diaminobenzidine (DAB) solution. Tissues were
counterstained with harris’ hematoxylin and then dehy-
drated. Slides were viewed and photographed under a
light microscope and analyzed using Image-Pro Plus
software (version 6.2) program (Media Cybernetics).
Statistical analysis
All statistical analysis was performed by SPSS software
(version 13.0). All the quantitative data were expressed
as mean values ± standard deviation, the significant dif-
ference between two groups was assessed by a two-tailed
Student’s t test. p < 0.05 represented a statistically signifi-
cant difference.
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Results
HK-2 was highly expressed in HCC cell lines and tumor
tissue
First, the expression of HK-2 was assessed by western
blotting in six HCC cell lines. As the results shown in
Fig. 1a, comparing to the normal hepatic cell LO2 in
which no HK-2 expression was detected, at least five
HCC cell lines (HepG2, Hep3B, HCC-LM3, SMMC-
7721, BEL-7402) expressed high levels of HK-2. We next
sought to examine HK-2 expression in HCC tissue and
paired adjacent normal tissue. Consistent with the result
in HCC cell lines, in matched normal adjacent samples,
HK-2 was not detectable or at a relatively low level. In
contrast, HK-2 was substantially overexpressed in
tumor samples (n = 75, p < 0.001) (Fig. 1b). These re-
sults suggested that HK-2 might have a role in HCC
development.
Chrysin inhibited HCC proliferation and glucose
metabolism
Since HK-2 was found to be of high expression in the
majority of tested HCC cells, we examined the activ-
ity of chrysin in HCC cells with high HK-2 expres-
sion. As shown in Fig. 2b, after chrysin treatment,
cell proliferation in LM-3, SMMC-7721 and Bel-7402
was substantially inhibited, and more than 50% cell
growth inhibition was observed after 72 h treatment.
Previous studies reported that tumor cells with high
HK-2 expression often displayed high glycolytic
phenomenon, we also investigated the effect of chry-
sin on tumor glycolysis. HCC cells exposed to chrysin
(30 μM) showed significantly lower glucose consump-
tion than the untreated. Along with the decrease of
glucose uptake, the secretion of lactate, which is the
product of tumor glycolysis, was also dramatically de-
creased (Fig. 2c-e). In accordance with the suppres-
sion of tumor glycolysis, in all tested HCC cells, the
expression of HK-2 was markedly decreased in a
dose-dependent manner (Fig. 2c-e). All these data
demonstrated that chrysin displayed an inhibitory ef-
fect against cell proliferation and glycolysis in HCC
cells via reducing HK-2 expression.
Chrysin induced HCC cell apoptosis via reducing HK-2 in
mitochondria
Generally, HK-2 is located on the out membrane of
mitochondria to exert it biological function. In order
to further confirm the effect of chrysin on HK-2, we
examined the change of HK-2 in mitochondria frac-
tions. As expected, HK-2 in mitochondria was sub-
stantially decreased in a dose-dependent manner after
exposure to chrysin (Fig. 3a). On the outer membrane
A
B
Fig. 1 Aberrant expression of HK-2 in hepatocellular carcinoma(HCC). a, HK-2 was highly expressed in HCC cell lines. Western blotting was performed
to examine HK-2 expression in several HCC cell lines and normal hepatic cell LO2. b, HK-2 was highly expressed in HCC tissue. Representative figures of
immunohistochemical staining for HK-2 in HCC tissues and paired adjacent normal tissue (left panel), statistical results of HK-2 staining in 75 different
HCC tissues and matched adjacent normal tissue (right panel). The asterisk (***, p < 0.001) indicated a significant difference of HK-2 expression between
tumor and paired adjacent normal tissue
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of mitochondria, HK-2 interacts with VDAC-1 to form
complex to prevent cancer cell apoptosis. Results of
immunoprecipitation assay showed that, with the re-
duction of HK-2 in mitochondria, the HK-2 which
bound to VDAC-1 was significantly decreased accord-
ingly (Fig. 3b). Furthermore, as shown in Fig. 3c,
cleaved caspase-3 and PARP, which are important
markers indicating cell apoptosis, were dramatically
elevated, suggesting that the decrease of HK-2 and
disruption of HK-2/VDAC-1 interaction caused by
chrysin resulted in HCC apoptosis.
Overexpression of HK-2 attenuated chrysin-mediated
glycolysis suppression and cell apoptosis
In order to further illustrate the role of HK-2 played in






Fig. 2 Chrysin inhibited cell proliferation and glycolysis in HCC cells. a, The chemical structure of chrysin. b, HCC cells were treated with indicated
concentration of chrysin for indicated times, cell proliferation was measured as described in Material and Methods. The asterisk (*, p < 0.05)
indicated a significant decrease of HCC cell proliferation after chrysin treatment. c-e, chrysin suppressed glycolysis in HCC-LM3 (top), SMMC-7721
(middle) and Bel-7402 (bottom) cells. HCC cells were treated with various concentrations of chrysin for 8 h and the cell lysates were subjected to
SDS-PAGE to examine the change of indicated protein (left panels). Glucose consumption (middle panels) and lactate production (right panels) in
cell culture medium were analyzed. The graph showed the data of at least three independent experiments expressed as means ± SD, the asterisks
(*, p < 0.05, **, p < 0.01, ***, p < 0.001, Student’s t test) indicated significant inhibition of glucose consumption and lactate secretion after
chrysin treatment
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with pORF-HK-2 to overexpress HK-2 and then investi-
gated chrysin’s activity. As shown in Fig. 4a, after trans-
fection, reduction of HK-2 caused by chrysin was
substantially recovered. With the increase of HK-2,
chrysin-mediated suppression of tumor glycolysis was
significantly impaired in HK-2-overexpression cells
(Fig. 4b). Moreover, in contrast with the mock group,
cleaved caspase-3 and PARP were significantly decreased
in HK-2 overexpression group, suggesting cell apoptosis
induced by chrysin was attenuated (Fig. 4a). Flow cytom-
etry analysis also demonstrated that over 20% HCC cells
were undergone apoptosis after treated with 60 μM
chrysin, however, the ratio of cell induced apoptosis was
significantly decreased in HK-2 overexpression cells. All
these results verified chrysin-mediated suppression of
glycolysis and induction of apoptosis in HCC cells was
closely related to its effect on HK-2.
Chrysin-induced apoptosis was attributed to activation of
Bax
Involvement of mitochondria in cell apoptosis is consid-
ered to be the common mechanism. In order to clarify
the mechanism by which chrysin induced HCC cell
apoptosis, we investigated the change of pro-apoptotic
and anti-apoptotic protein in cytosolic and mitochondria
fractions respectively. In HCC-LM3 and SMMC-7721
cells, cytochrome C was significantly increased in the
cytosolic fractions after chrysin treatment (Fig. 5a and
b). Conversely, Bax, which is a pro-apoptotic protein,
was found to be translocated to mitochondria. With the
decrease in cytosolic, its expression in mitochondria was
dramatically increased. Other proteins involved in apop-
tosis regulation such as Bak, Bcl-2, Bcl-xL had no
obvious change in chrysin treated cells (Fig. 5a-d). In




Fig. 3 Chrysin induced HCC cell apoptosis by reducing HK-2 in mitochondria. a, HCC cells were treated with chrysin for 24 h, the mitochondria
fractions was extracted and examined by western blotting to detect the change of indicated protein. b, HCC-LM3 cell was treated with chrysin
for 24 h and the lysates of mitochondria fractions were immunoprecipitated with HK-2 or VDAC-1 antibodies, then the binding affinity was analyzed
with western blotting analysis. c, HCC cells were treated with various chrysin for 24 h and cell lysates were probed with indicated antibodies
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cytosolic to mitochondria was substantially attenuated,
and the cytochrome C released from mitochondria into
cytoplasm was also impaired, indicating that cell apop-
tosis induced by chrysin was attributed to the Bax acti-
vation on mitochondria.
Chrysin restrained HCC xenograft growth in vivo
To validate the antitumor activity of chrysin against
HCC, the efficacy of chrysin was assessed in HCC-LM3
xenograft model. As shown in Fig. 6a-d, comparing with
the vehicle group, tumor growth in chrysin group was
significantly suppressed. In the end of experiment, the
tumor volume of vehicle group had reached about
500 mm3, while the average tumor volume of chrysin
group was around 200 mm3. Meanwhile, no obvious tox-
icity was observed as evaluating the change of body
weight. Immunohistochemistry analysis of chrysin-
treated tumor tissue demonstrated the expression of
HK-2 in tumor tissue was substantially decreased after
chrysin treatment, which confirmed the effect of chrysin
on HK-2 in vivo (Fig. 6e). Ki-67 is a well-known marker
to represent the potential of cell proliferation, Ki67 in
chrysin group was substantially decreased in contrast
with the vehicle group. With the suppression of glycoly-
sis by reducing HK-2 in tumor tissue, energy supply to
sustain tumor growth was blocked, and the proliferative
capability of tumor cell was weakened.
Discussion
In present study, our results demonstrated that chrysin
had profound potency against HCC in vitro and in vivo.
Mechanism investigations revealed that HK-2 played a
pivotal role for chrysin to exert its activity in HCC. With




Fig. 4 Overexpression of HK-2 impaired the effect of chrysin on apoptosis and tumor glycolysis. a, activated caspase-3 and PARP in HCC cell with
exogenous HK-2 expression. HCC cells were transfected with pORF-HK-2, 24 h later, the cells were treated with 60 μM chrysin, cell lysates were
subjected to SDS-PAGE and probed with indicated protein. b and c, the effect of chrysin on glycolysis and apoptosis in HK-2 overexpressed HCC-
LM3 cells. HCC-LM3 cell was transfected with pORF-HK-2 for 24 h and seeded in 6 well plates for 10 h, then exposed to 60 μM chrysin, tumor
glycolysis (b) and apoptosis (c) was examined at 8 h and 24 h, respectively. b, The graph showed the data of at least three independent experiments
expressed as means ± SD, the asterisks (*, p < 0.05, **, p < 0.01, ***, p < 0.001, Student’s t test) indicated significant difference between different groups.
c, Representative FACS results of Annexin V-PI double staining were shown (left panels), and the graph (right panel) showed the data of at least three
independent experiments expressed as means ± SD, the asterisks (***, p < 0.001, Student’s t test) indicated a significant difference
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glycolysis in HCC was markedly inhibited. Except the ef-
fect on HCC glycolysis, HK-2 was also proved to be in-
volved in chrysin-induced apoptosis. Exposure to chrysin
resulted in the decrease of the interaction between HK-2
and VDAC-1, which caused the release of pro-apoptotic
proteins from mitochondrial and induced tumor cells to
undergo apoptosis.
The expression of HK-2 was reported to be elevated in
many cancers and was considered a predictive marker of
poor prognosis of HCC [23, 24], breast [25], and gastric
cancer [26]. Consistent with previous report, HK-2 ex-
pression was detected to be of high rate in most tested
HCC cell lines and tumor tissue in contrast with the
normal hepatic cell and tissue in our studies (Fig. 1). Dai
W et al. demonstrated that HCC cells with high HK-2
expression displayed high aerobic glycolysis, as indicated
by increased glucose uptake and lactate production [27].
After chrysin treatment, with the reduction of HK-2,
glucose consumption and lactate production in HCC
cells were dramatically decreased (Fig. 2). Further inves-
tigations revealed that the suppression caused by chrysin
was substantially attenuated after overexpression of HK-
2, suggesting HK-2 played an important role in chrysin-
mediated glycolysis suppression. Metabolic control
A B
C D
Fig. 5 Chrysin induced Bax activation on mitochondrial. HCC cells were transfected with pORF-HK-2, 24 h later, the cells were treated with 60 μM
chrysin for another 24 h, and subcellular fractions were prepared and subjected to SDS-PAGE and probed with indicated protein. a and b, cytosolic
Bax, Bak and chrome c expressions in HCC-LM3 cell (a) and SMMC-7721 cell (b) were tested by western blotting. c and d, mitochondrial Bax, Bak, Bcl2,
Bcl-xl, chrome c, and HK2 in HCC-LM3 cell (c) and SMMC-7721 cell (d) were tested by western blotting
Xu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:44 Page 8 of 11
analysis of HCC cell lines demonstrated that the main
control of glycolytic flux was exerted by HKs [28]. Along
with the increase of HK-2, altered glucose metabolism
often conferred cancer cells resistance to chemotherapy,
it was evidenced that the sensitivity of tumor cells to
chemotherapy were substantially enhanced via glycolysis
inhibition by targeting HK-2 [29, 30]. Given the activity
of chrysin against HK-2 and glycolysis, we thought chry-
sin had the potential to strengthen the efficacy of other
chemotherapies.
Previous studies had shown that induction of apop-
tosis was a key molecular mechanism responsible for the
antitumor activity of chrysin. It has been shown that
chrysin caused non-small cell lung cancer A549 to
undergo apoptosis via the increase of the Bax/Bcl-2 ratio
and activation of caspase-3 and −9 [31]. Moreover, chry-
sin acted as a histone deacetylase (HDAC) inhibitor to
induce apoptosis in melanoma A375 by decreasing
HDAC targeted gene such as Bcl-xL, Survivin and in-
creasing the level of caspase-3 protein [32]. It also has
been depicted in many studies that induction of ROS
and depletion of GSH played a significant role in apop-
tosis induced by chrysin [33, 34]. Different from previ-
ous report, no obvious change of anti-apoptotic protein,
such as Bcl-xL and Bcl-2 was observed in our study.




Fig. 6 Chrysin inhibited HCC-LM3 xenograft growth in vivo. Nude mice with HCC-LM3 xenograft were randomly divided to groups when tumor
volume reached 50 to 100 mm3. 30 mg/kg chrysin was administrated three times weekly by intraperitoneal injection. a, photograph of tumors in
vehicle and chrysin-treated group; b, the change of body weight of tumor bearing mice; c, tumor growth curve in vehicle and treated group; d,
tumor weight in vehicle and chrysin group; e, tumor tissues were subjected to immunohistochemistry staining with indicated antibodies to detect the
change of HK-2, Ki67 after chrysin treatment
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mainly attributed to the reduction of HK-2. By position-
ing itself on the outer membrane of mitochondria, the
formation of VDAC-1 and HK-2 complex modulated the
integrity and permeability of mitochondria membrane.
With the decrease of HK-2 in mitochondria, the inter-
action between HK-2 and VDAC was disrupted, which
resulted in dramatic increase of membrane permeability
and release of pro-apoptotic enzyme, such as cyto-
chrome C. Bax in cytoplasm was significantly decreased
after chrysin treatment, but Bax located on mitochon-
dria was substantially increased, implying that the major-
ity of Bax was transferred from cytoplasm to
mitochondria after HCC cells exposed to chrysin. It was
found recombinant Bax induced permeability in lipo-
somes containing VDAC [35], and Bax-activated cyto-
chrome C release was blocked by intracellular
microinjection of anti-VDAC antibodies [36]. Moreover,
electrophysiological studies revealed that Bax and VDAC
combination gave rise to 4 and 10 times increase in con-
ductance in compare with VDAC and Bax channels
alone respectively [37]. Pastorino JG et al. reported that
HK-2 competed with Bax for interaction with VDAC,
and detachment of HK-2 promoted the binding of Bax
to VDAC [38]. Therefore, we speculated that owing to
the decrease of HK-2 on mitochondria, Bax was more
readily to gain access to VDAC, the formation of
VDAC-Bax complex was capable of passing cytochrome
C and other pro-apoptotic proteins, which induced cell
apoptosis. With HK-2 overexpression, Bax binding to
VDAC was hindered, and chrysin- induced apoptosis
was significantly impaired.
The regulation of HK-2 expression in tumor cells is
complicated. Like other enzymes in glycolytic pathway,
HK-2 expression is primarily regulated by c-myc, HIF-1α
and p53 [39]. Moreover, microRNAs such as miR-143 and
miR-155 were evidenced to be capable of modulating HK-
2 expression [40, 41]. Fu B et al. reported that chrysin sup-
pressed HIF-1α expression via reducing its stability and
inhibiting its synthesis [42]. In our studies, HK-2 was vali-
dated to be decreased and reduction of HK-2 played a piv-
otal role for chrysin to perform its activity in HCC, but
further investigations is needed to elaborate the exact
mechanism by which chrysin to affect HK-2 expression.
Conclusion
In conclusion, the results of this study demonstrated
chrysin had profound antitumor activity against HCC via
inhibiting tumor glycolysis and inducing cell apoptosis.
Different from the mechanism reported by previous
studies, reduction of HK-2 was an important underlying
mechanism for chrysin to exert its effect on cell metab-
olism and cell apoptosis. This study provided a novel
preclinical rational for chrysin, or its analogue, to be ap-
plied for HCC management.
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